Clinical trials: Advanced Small Bowel Adenocarcinoma, open to volunteers
Advanced Small Bowel Adenocarcinoma
Sacituzumab Tirumotecan (MK-2870) in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-Based Combination Therapy
Small bowel adenocarcinoma is a rare cancer with a poor prognosis. For patients with locally advanced or metastatic disease, the usual first treatment is chemotherapy with platinum-based combinations such as FOLFOX or CapeOX.
- Trial name
- METROPOLIS (NCT07720258)
- Testing
- Sacituzumab tirumotecan
- Where
- 5 sites in Japan
- Volunteers
- 27 people
- Sponsor
- National Cancer Center, Japan
Advanced Small Bowel Adenocarcinoma
Enfortumab Vedotin in Patients With Advanced Small Bowel Adenocarcinoma Refractory or Intolerant to Platinum-based Combination Therapy
Small bowel adenocarcinoma is a rare cancer with a poor prognosis. For patients with locally advanced or metastatic disease, the usual first treatment is chemotherapy with platinum-based combinations such as FOLFOX or CapeOX.
- Trial name
- ENVELOPE (NCT07347314)
- Testing
- Enfortumab vedotin
- Where
- 3 sites in Japan
- Volunteers
- 27 people
- Sponsor
- National Cancer Center, Japan
Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Trial Evaluating Modified FOLFIRINOX and Modified FOLFOX in the Treatment of Locally Advanced or Metastatic Small Bowel Adenocarcinoma
Randomized, non-comparative, open-label, multi-centre Phase II study to evaluate modified FOLFIRINOX and modified FOLFOX in the locally advenced or metastatic small bowel adenocarcinoma.
- Trial name
- FOLFORINOX SBA (NCT06278545)
- Testing
- modified FOLFORINOX, Modified FOLFOX
- Where
- France
- Volunteers
- 130 people
- Sponsor
- Centre Hospitalier Universitaire Dijon